Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAMAinDiab: Lisdexamfetamine vs Methylphenidate in Pediatric ADHD with T1D
NCT05957055Phase 2Recruiting
- Sponsor
- Medical University of Lodz
- Start
- Feb 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lisdexamfetamine in attention deficit hyperactivity disorder (ADHD), sponsored by Medical University of Lodz. Started Feb 2024; status: recruiting.
02
Drugs
lisdexamfetamine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT05957055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05957055.